Login / Signup

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Nancy A KernanPaul G RichardsonAngela R SmithBrandon M TriplettJoseph H AntinLeslie LehmannYoav H MessingerWei LiangRobin HumeWilliam TappeRobert J SoifferStephan A Grupp
Published in: Pediatric blood & cancer (2018)
In this post hoc analysis of 82 patients initiating defibrotide within 30 days of starting chemotherapy, Kaplan-Meier estimated survival was 74.1% at 70 days after defibrotide initiation. Safety profile was consistent with prior defibrotide studies.
Keyphrases